ArticleMolecular cancer research : MCR2019
Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2023Pooled it
- Cribriform Tumor Burden in Grade Group 4 Prostate Cancer: A Quantitative Threshold Predicting Lymphovascular Invasion and Metastasis.Journal of clinical medicine · 2026Article
- Long-term performance of the Gleason score in predicting metastatic and fatal prostate cancer.American journal of epidemiology · 2026Article
- International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.The American journal of surgical pathology · 2025Article
- Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.Future oncology (London, England) · 2025Review
- GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer.Neoplasia (New York, N.Y.) · 2024Article
- Cribriform pattern 4/intraductal carcinoma of the prostate and persistent prostate-specific antigen after radical prostatectomy.BJUI compass · 2024Article
- Review
- Prognostic Significance of the Cribriform Pattern in Prostate Cancer: Clinical Outcomes and Genomic Alterations.Cancers · 2024Article
- Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases.American journal of clinical and experimental urology · 2024Article
- The presence of cribriform pattern in prostate biopsy and radical prostatectomy is associated with negative postoperative pathological features.Central European journal of urology · 2024Article
- Molecular complexity of intraductal carcinoma of the prostate.Cancer medicine · 2024Review
- Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?The Prostate · 2023Article
- Review
- 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Active surveillance should be considered for select men with Grade Group 2 prostate cancer.BMC urology · 2023Review
- Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimens.World journal of urology · 2022Article
- Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease.Nature communications · 2022Article
- AZIN1 RNA editing alters protein interactions, leading to nuclear translocation and worse outcomes in prostate cancer.Experimental & molecular medicine · 2022Article
- WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.Histopathology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 5 countries.
Funding
Abstract
Among prostate cancers containing Gleason pattern 4, cribriform morphology is associated with unfavorable clinicopathologic factors, but its genetic features and association with long-term outcomes are incompletely understood. In this study, genetic, transcriptional, and epigenetic features of invasive cribriform carcinoma (ICC) tumors were compared with non-cribriform Gleason 4 (NC4) in The Cancer Genome Atlas (TCGA) cohort. ICC (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.